BR112012009500A2 - utilidade médica de proteínas de ligação de glicano e glicanos - Google Patents

utilidade médica de proteínas de ligação de glicano e glicanos

Info

Publication number
BR112012009500A2
BR112012009500A2 BR112012009500A BR112012009500A BR112012009500A2 BR 112012009500 A2 BR112012009500 A2 BR 112012009500A2 BR 112012009500 A BR112012009500 A BR 112012009500A BR 112012009500 A BR112012009500 A BR 112012009500A BR 112012009500 A2 BR112012009500 A2 BR 112012009500A2
Authority
BR
Brazil
Prior art keywords
glycan
identifying
present
binding polypeptides
binding proteins
Prior art date
Application number
BR112012009500A
Other languages
English (en)
Inventor
Alex Butschi
Markus Aebi
Markus Kunzler
Martin Wälti
Michael Hengartner
Original Assignee
Eth Zuerich
Univ Zürich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eth Zuerich, Univ Zürich filed Critical Eth Zuerich
Publication of BR112012009500A2 publication Critical patent/BR112012009500A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Husbandry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Botany (AREA)
  • Toxicology (AREA)

Abstract

utilidade médica de proteínas de ligação de glicano e glicanos. a presente invenção refere-se ao uso de polipeptídeos de ligação de glicano e glicanos como um medicamento, em particular para tratar e/ou previnir infecções helmínticas ou uma doença imune. além disso, a presente invenção é dirigida a composições farmacêuticas correspondentes, produtos de alimento e alimentação animal compreendendo glicanos isolados e/ou polipeptídeos de ligação de glicano. além disso, a presente invenção ensina métodos para identificar polipeptídeos de ligação de carboidrato anti-heimínticos, para identificar glicano helmíntico e alvos de gene envolvidos em toxicidade mediada por glicano, para identificar helmintos suscetíveis a toxicidade mediada por glicano, e para identificar substâncias anti-helmínticas e antialérgicas.
BR112012009500A 2009-10-21 2010-10-12 utilidade médica de proteínas de ligação de glicano e glicanos BR112012009500A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09013283 2009-10-21
PCT/EP2010/006228 WO2011047794A2 (en) 2009-10-21 2010-10-12 Medical utility of glycan-binding proteins and glycans

Publications (1)

Publication Number Publication Date
BR112012009500A2 true BR112012009500A2 (pt) 2016-11-29

Family

ID=43662200

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009500A BR112012009500A2 (pt) 2009-10-21 2010-10-12 utilidade médica de proteínas de ligação de glicano e glicanos

Country Status (9)

Country Link
US (1) US20120207737A1 (pt)
EP (2) EP2490707B1 (pt)
JP (2) JP2013508319A (pt)
AU (1) AU2010310122B2 (pt)
BR (1) BR112012009500A2 (pt)
CA (1) CA2777883A1 (pt)
NZ (1) NZ599153A (pt)
WO (1) WO2011047794A2 (pt)
ZA (1) ZA201202134B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013182603A1 (en) 2012-06-06 2013-12-12 University Of Natural Resources And Life Sciences Vienna New n-glycans and uses thereof
CN111558034B (zh) * 2020-04-16 2023-03-24 南京农业大学 一种捻转血矛线虫纳米材料亚单位疫苗及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812181A1 (de) * 1988-04-13 1989-10-26 Werner E G Prof Dr Mueller Arzneimittel, enthaltend natuerliche und/oder chemisch modifizierte mono- oder polysaccharide und deren verwendung
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5707817A (en) 1993-02-05 1998-01-13 Colorado State University Research Foundation Carbohydrate-based vaccine and diagnostic reagent for trichinosis
DE69630307T2 (de) * 1995-08-03 2004-07-15 The Board Of Regents Of The University Of Oklahoma, Norman O-glycaninhibitoren von selectinvermittelten entzüngen
PL203789B1 (pl) * 1999-03-12 2009-11-30 Univ Massachusetts Kompozycje wywołujące u ssaka ochronną odpowiedź immunologiczną i ich zastosowanie do wywoływania u kręgowca ochronnej odpowiedzi immunologicznej wobec eukariotycznego pasożyta, wydzielone lipoglikany oraz otrzymane z nich wydzielone oligosacharydy
US20060121029A1 (en) * 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
US20060009378A1 (en) * 2002-11-14 2006-01-12 Itshak Golan Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
AU2004311543B2 (en) * 2003-12-12 2012-01-19 Iq Corporation Methods of inducing IL-10 production
WO2005088310A2 (en) * 2004-03-05 2005-09-22 The Scripps Research Institute High throughput glycan microarrays
WO2005092368A1 (en) * 2004-03-26 2005-10-06 Charite-Universität- Smedizin Berlin Uses of galectin-2
WO2007085057A1 (en) * 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
WO2008142483A2 (en) * 2006-12-14 2008-11-27 Plant Research International B.V. Vaccine compositions and methods of use thereof

Also Published As

Publication number Publication date
WO2011047794A3 (en) 2011-10-13
NZ599153A (en) 2014-04-30
AU2010310122B2 (en) 2014-05-22
AU2010310122A1 (en) 2012-04-19
EP2494980A3 (en) 2013-03-13
US20120207737A1 (en) 2012-08-16
CA2777883A1 (en) 2011-04-28
EP2494980A2 (en) 2012-09-05
JP2015096501A (ja) 2015-05-21
EP2490707A2 (en) 2012-08-29
WO2011047794A2 (en) 2011-04-28
EP2490707B1 (en) 2016-07-27
ZA201202134B (en) 2013-05-29
JP2013508319A (ja) 2013-03-07

Similar Documents

Publication Publication Date Title
CY1120885T1 (el) Παραγωγα πυρρολο[3,2-d]πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112015026830A8 (pt) composto, composição farmacêutica, combinação, produto, uso de um composto, e, método para profilaxia ou tratamento de um estado de doença ou condição
BR112014029709A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença mediados por uma fgfr cinase
WO2015037000A8 (en) Vstm5 polypeptides and uses thereof for treatment of cancer, infectious diseases and immune related diseases
BR112018002130A2 (pt) anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1)
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
BR112015014372A2 (pt) inibidores de autotaxina
BR112017001623A2 (pt) sais de berberina, sais ursodesoxicólico e combinações, métodos de preparação e aplicação dos mesmos
DOP2013000280A (es) Proteínas de unión a antígeno
BR112015021414A2 (pt) vírus da doença newcastle e seus usos
BR112014029706A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença mediados por uma fgfr cinase
TR201905586T4 (tr) Amorf dapagli̇flozi̇n i̇çeren formülasyonlar
BR112015008447A2 (pt) métodos para tratar câncer
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
BR122020008544B8 (pt) uso de 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas, e medicamento
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
BR112014016810A2 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112014007223A2 (pt) derivados de estra-1,3,5(10),16-tetraeno-3-carboxamida, processos para sua preparação, preparações farmacêuticas compreendendo os mesmos e seu uso para preparar medicamentos
EA201500112A1 (ru) 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств
BR112012002265A2 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
BR112017000898A2 (pt) oritavancina de alta pureza e método de produção da mesma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: G01N 33/50 (2006.01), A23K 20/10 (2016.01), A23K 2